PMID- 25685165
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150216
LR  - 20200930
IS  - 1735-143X (Print)
IS  - 1735-3408 (Electronic)
IS  - 1735-143X (Linking)
VI  - 14
IP  - 12
DP  - 2014 Dec
TI  - Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular 
      Carcinoma Development and Progression.
PG  - e23552
LID - 10.5812/hepatmon.23552 [doi]
LID - e23552
AB  - BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most important health 
      problems in China. OBJECTIVES: This study analyzed expression of high-mobility 
      group protein B1 (HMGB1) and inhibitor of apoptosis protein-2 (c-IAP2) proteins 
      in HCC compared to paired para-tumor tissue samples to assess the association 
      with HCC pathogenesis and progression. MATERIALS AND METHODS: Sixty-eight HCC and 
      para-tumor tissue samples were collected for Western blot, qRT-PCR and 
      immunohistochemical analyses of HMGB1 and c-IAP2. RESULTS: HMGB1 and c-IAP2 
      proteins were highly expressed in HCC tissue samples [85.3% (58/68) and 82.4% 
      (56/68), respectively] compared to para-tumor tissue samples [32.3% and 27.9%, 
      respectively]. Furthermore, expression of HMGB1 was significantly associated with 
      enhanced c-IAP2 expression in HCC tissue samples (r = 0.878, P < 0.01). 
      Expression of HMGB1 was associated with tumor multiplicity and size, 
      alpha-fetoprotein (AFP) level and advanced TNM stage, while expression of c-IAP2 
      was associated with tumor size, AFP level and advanced TNM stage. CONCLUSIONS: 
      Expression of HMGB1 and c-IAP2 proteins was associated with HCC development and 
      progression, and the expression of HMGB1 and c-IAP2 proteins in HCC were 
      significantly associated with each other. Additionally, these proteins may show 
      promise as biomarkers to predict HCC progression.
FAU - Bi, Man Ru
AU  - Bi MR
AD  - The Second Clinical Medical College, Harbin Medical University, Harbin, China.
FAU - Zhu, Li Ying
AU  - Zhu LY
AD  - The Fourth Clinical Medical College, Harbin Medical University, Harbin, China.
FAU - Yan, Bing Zhu
AU  - Yan BZ
AD  - The Second Clinical Medical College, Harbin Medical University, Harbin, China.
FAU - Chen, Li Yan
AU  - Chen LY
AD  - The Second Clinical Medical College, Harbin Medical University, Harbin, China.
FAU - Wang, Fu Xiang
AU  - Wang FX
AD  - The Fourth Clinical Medical College, Harbin Medical University, Harbin, China.
FAU - Ma, Ying Ji
AU  - Ma YJ
AD  - The Fourth Clinical Medical College, Harbin Medical University, Harbin, China.
FAU - Yang, Bao Shan
AU  - Yang BS
AD  - The Second Clinical Medical College, Harbin Medical University, Harbin, China.
LA  - eng
PT  - Journal Article
DEP - 20141215
PL  - Netherlands
TA  - Hepat Mon
JT  - Hepatitis monthly
JID - 101277874
PMC - PMC4310020
OTO - NOTNLM
OT  - Biomarkers
OT  - HMGB1
OT  - Hepatocellular Carcinoma
OT  - c-IAP2 Protein
EDAT- 2015/02/17 06:00
MHDA- 2015/02/17 06:01
PMCR- 2014/12/15
CRDT- 2015/02/17 06:00
PHST- 2014/09/12 00:00 [received]
PHST- 2014/11/20 00:00 [revised]
PHST- 2014/11/29 00:00 [accepted]
PHST- 2015/02/17 06:00 [entrez]
PHST- 2015/02/17 06:00 [pubmed]
PHST- 2015/02/17 06:01 [medline]
PHST- 2014/12/15 00:00 [pmc-release]
AID - 10.5812/hepatmon.23552 [doi]
PST - epublish
SO  - Hepat Mon. 2014 Dec 15;14(12):e23552. doi: 10.5812/hepatmon.23552. eCollection 
      2014 Dec.